Clinical Report: Receptor Expression Influences Targeting of CD8+ T Cells

Overview

Revise to emphasize the implications of PD-1 receptor density and T cell subset prevalence on treatment outcomes.

Background

The efficacy of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis has been established in oncology, yet many patients do not respond or develop resistance. Eciskafusp alfa (PD1-IL2v) represents a novel approach designed to enhance IL-2 signaling specifically in PD-1+ T cells while minimizing activation of immunosuppressive Tregs. Understanding the targeting mechanisms of PD1-IL2v is crucial for optimizing therapeutic strategies in solid tumors.

Data Highlights

Key Findings

• PD-1 receptor density is significantly higher in CD8+ TILs than in PBMCs.
• Eciskafusp alfa preferentially targets stem-like and effector CD8+ T cells.
• Induces superior biological activity in CD8+ T cells compared to Tregs.
• Identifies PD-1 receptor density as a potential biomarker for patient selection.
• Minimizes Treg activation while enhancing intra-tumoral immune stimulation.

Clinical Implications

Detail practical applications of PD-1 receptor density measurements in clinical settings.

Conclusion

Eciskafusp alfa demonstrates a promising approach to selectively enhance CD8+ T cell activity in tumors while reducing Treg activation. Further research may solidify its role in improving patient outcomes in solid tumors.

Related Resources & Content

1. Frontiers, Source, 2026 -- Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients
2. The ASCO Post, Source, 2015 -- Ex Vivo Manipulation of Tumor Microenvironment Improves Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
3. Blood Cancer Journal, Source, 2021 -- Epcoritamab Demonstrates Strong Anti-Tumor Efficacy Against Malignant B-Cells in Patients with DLBCL, FL, and MCL
4. dana-farber, Source, 2021 -- Phenotype, Specificity and Avidity of Antitumour CD8+ T Cells in Melanoma
5. ASCO, Source, 2026 -- Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
6. Advancements in Renal Cell Carcinoma Treatment: Transitioning from Molecular Therapies to Targeted Immunotherapy
7. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0 | Journal of Clinical Oncology
8. Frontiers | Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients